Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) SVP Brett P. Monia unloaded 79 shares of the company’s stock on the open market in a transaction that occurred on Thursday, July 31st. The stock was sold at an average price of $31.50, for a total transaction of $2,488.50. Following the sale, the senior vice president now directly owns 1,813 shares in the company, valued at approximately $57,110. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. ISIS Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $41.10.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 1.90% during mid-day trading on Friday, hitting $30.40. The stock had a trading volume of 1,445,586 shares. ISIS Pharmaceuticals has a 52 week low of $22.25 and a 52 week high of $62.66. The stock’s 50-day moving average is $32.45 and its 200-day moving average is $38.23. The company’s market cap is $3.574 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter last year, the company posted ($0.02) earnings per share. ISIS Pharmaceuticals’s revenue was down 35.0% compared to the same quarter last year. Analysts expect that ISIS Pharmaceuticals will post $-0.71 EPS for the current fiscal year.

Receive News & Ratings for ISIS Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ISIS Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.